Merck, known as MSD outside the United States and Canada, MRK and
Endocyte, Inc. ECYT today announced the online publication of
results from the randomized Phase II PRECEDENT trial for vintafolide
(MK-8109/EC145), an investigational folate small molecule drug conjugate
(SMDC), in the Journal of Clinical Oncology (JCO), the official journal of the
American Society of Clinical Oncology. These trial results are the basis for
the vintafolide regulatory application currently under review with the
European Medicines Agency for the treatment of folate-receptor positive
platinum-resistant ovarian cancer in combination with pegylated liposomal
doxorubicin (PLD). Enrollment is ongoing in the pivotal Phase III PROCEED
clinical trial with vintafolide, along with investigational companion imaging
agent etarfolatide (EC20), in platinum-resistant ovarian cancer
(Clinicaltrials.gov NCT01170650).
As reported in JCO online, results from the Phase II PRECEDENT trial showed
that administration of vintafolide plus pegylated liposomal doxorubicin (PLD)
versus PLD alone in women with platinum-resistant ovarian cancer resulted in a
median progression-free survival (PFS) of 5.0 months compared to 2.7 months
for those treated with PLD alone (HR=0.63; 95% CI 0.41–0.96; p=0.031) in the
intent-to-treat (ITT) population. Those patients shown to have folate
receptor-positive tumors, as defined by all selected target lesions being
folate receptor-positive (FR%100) using the investigational folate
receptor-targeted companion diagnostic imaging agent etarfolatide,
demonstrated greater benefit, as measured by PFS, from treatment with
vintafolide plus PLD versus PLD alone. Median PFS benefit in these patients
was 5.5 months compared to 1.5 months for PLD alone (HR=0.38; 95% CI
0.17–0.85; p=0.013). Etarfolatide is being developed by Endocyte as a
non-invasive method to identify tumors that express the folate receptor.
“The combination of vintafolide plus PLD demonstrated significant improvement
in progression-free survival over standard treatment in women with folate
receptor-positive platinum-resistant ovarian cancer,” said R. Wendel Naumann,
M.D., Associate Director, Gynecologic Oncology, Carolinas HealthCare System's
Levine Cancer Institute, Charlotte, N.C., and corresponding author of the
publication. “Targeting the folate receptor, which is expressed on the
majority of epithelial ovarian cancers, is a potentially promising strategy,
especially when combined with a companion diagnostic that is designed to
identify patients who are most likely to respond to the treatment, a hallmark
of personalized medicine.”
The Phase II PRECEDENT trial was an international, multi-center, randomized
study of 149 women with platinum-resistant ovarian cancer. ^ Patients were
randomized to receive vintafolide plus PLD or PLD alone at a standard dose,
until disease progression or death. The primary endpoint of the study was PFS.
Secondary endpoints included response rate and overall survival (OS). In the
ITT population, no difference was observed in overall survival (HR=1.010; 95%
CI 0.679–1.503; p=0.957). Endocyte first presented results from the Phase II
PRECEDENT trial at the 2011 American Society of Clinical Oncology Annual
Meeting.
The combination of vintafolide and PLD was generally well tolerated, and no
drug-related mortality or statistically significant difference in the
incidence of drug-related serious treatment-emergent adverse events (TEAEs)
was observed.
* In the vintafolide and PLD arm vs. PLD arm, anemia, neutropenia and
thrombocytopenia were reported in 16.6% vs. 10.4%, 19.1% vs. 10.4%, and
2.7% vs. 3.0% of all cycles, respectively.
* Stomatitis and palmar-plantar erythrodysesthesia (hand-foot syndrome)
occurred in 16.6% vs. 22.8%, and 19.1% vs.15.8% of cycles, respectively.
* The frequency of fatigue was similar between arms, 15.8% of vintafolide
and PLD arm cycles, and 14.9% of PLD arm cycles.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in